Pharma Industry News

AstraZeneca’s Eplontersen meets endpoints in critical phase 3 trial

Eplontersen significantly improved patient-reported quality of life following successful researchOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]